The development of novel medications for alcohol use disorder (AUD) is a NIAAA research priority. The Clinical Research Project is designed to translate the discoveries of preclinical TSRI-ARC investigators for potential therapeutic use using proof-of-concept human laboratory testing. This component has 2-way interactions with all the individual Research Projects of the ARC and the Animal Models Core. The animal work will validate the choices of a ?next generation? selective glucocorticoid receptor antagonist drug and a drug that is hypothesized to restore microtubule homeostasis, and the Clinical Research Project will validate these targets as potential therapeutics treatment of AUD. Should either target ultimately prove to be untenable to pursue human studies, other systems under study by the TSRI-ARC may be viable, such as specific glutamate, serotonin, or hypocretin targets. Drugs identified for human study will either be FDA-approved or available under an IND and will be selected by Dr. Mason based on scientific prioritization by the TSRI-ARC Steering Committee, Program Advisory Committee, and safety considerations. Drugs will be tested in a highly standardized, reliable, and valid human laboratory model informing the 3 stages of the addiction cycle: withdrawal/negative affect, preoccupation/anticipation, and binge/intoxication. Human laboratory results will serve as an analogue for drinking outcomes of clinical treatment trials. Subjects for each study will be 50 non- treatment-seeking male and female paid volunteers who meet DSM-5 criteria for AUD of ? moderate severity (AUD-MS). Studies are randomized, double-blind, and placebo-controlled. The treatment duration is at least 1- week and guided by drug pharmacokinetics. The primary endpoint is craving scores in response to in vivo alcohol cues presented in the laboratory with confirmatory physiological outcomes and naturalistic measures of drinking, negative affect, craving, sleep and executive function.
Specific Aim 1 : To evaluate TSRI-ARC drug candidates in paid non-treatment-seeking volunteers with current AUD-MS using the human lab model of the addiction cycle.
Specific Aim 2 : To identify potential biomarkers of clinical outcomes (e.g., peripheral markers of stress, including hypothalamic-pituitary-adrenal axis, serotonin, hypocretin, and measures of microtubule homeostasis) and drug plasma concentration. Safety Aim 3: To evaluate the safety and tolerability of TSRI- ARC drug candidates in subjects with AUD-MS as assessed by significant changes from baseline in EKG, routine blood and urine biochemistry, vital signs, physical exam, and subjective complaints relative to placebo. Hypothesis: The overall hypothesis under test is that, relative to placebo, novel drug candidates identified by the TSRI-ARC will significantly attenuate responsivity to alcohol cues in the human lab model and reduce drinking, craving, negative affect, insomnia and executive function deficits during treatment and 1-month follow-up. Interpretation of Results: Positive findings will provide clinical validation of stress targets identified by the TSRI-ARC and provide a rational basis for later phase testing of candidate drugs for AUD-MS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Comprehensive Center (P60)
Project #
5P60AA006420-37
Application #
9836782
Study Section
Special Emphasis Panel (ZAA1)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
McClatchy, Daniel B; Yu, Nam-Kyung; Martínez-Bartolomé, Salvador et al. (2018) Structural Analysis of Hippocampal Kinase Signal Transduction. ACS Chem Neurosci :
Berger, Anthony L; Henricks, Angela M; Lugo, Janelle M et al. (2018) The Lateral Habenula Directs Coping Styles Under Conditions of Stress via Recruitment of the Endocannabinoid System. Biol Psychiatry 84:611-623
Mason, Barbara J; Quello, Susan; Shadan, Farhad (2018) Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs 27:113-124
Varodayan, Florence P; Sidhu, Harpreet; Kreifeldt, Max et al. (2018) Morphological and functional evidence of increased excitatory signaling in the prelimbic cortex during ethanol withdrawal. Neuropharmacology 133:470-480
Matzeu, Alessandra; Martin-Fardon, Rémi (2018) Drug Seeking and Relapse: New Evidence of a Role for Orexin and Dynorphin Co-transmission in the Paraventricular Nucleus of the Thalamus. Front Neurol 9:720
Sidhu, Harpreet; Kreifeldt, Max; Contet, Candice (2018) Affective Disturbances During Withdrawal from Chronic Intermittent Ethanol Inhalation in C57BL/6J and DBA/2J Male Mice. Alcohol Clin Exp Res 42:1281-1290
Ehlers, Cindy L; Wills, Derek; Gilder, David A (2018) A history of binge drinking during adolescence is associated with poorer sleep quality in young adult Mexican Americans and American Indians. Psychopharmacology (Berl) 235:1775-1782
Pavon, Francisco J; Serrano, Antonia; Sidhpura, Nimish et al. (2018) Fatty acid amide hydrolase (FAAH) inactivation confers enhanced sensitivity to nicotine-induced dopamine release in the mouse nucleus accumbens. Addict Biol 23:723-734
Logrip, Marian L; Walker, John R; Ayanwuyi, Lydia O et al. (2018) Evaluation of Alcohol Preference and Drinking in msP Rats Bearing a Crhr1 Promoter Polymorphism. Front Psychiatry 9:28
Serrano, Antonia; Pavon, Francisco J; Buczynski, Matthew W et al. (2018) Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake. Neuropsychopharmacology 43:1840-1850

Showing the most recent 10 out of 211 publications